Moleculin Biotech, Inc. MBRX 深 沪
已收盘 01-30 16:00:00 美东时间
4.29
+0.010
+0.23%
华盛通- 最 高4.3992
- 今 开4.28
- 成交量 3.73万股
- 最 低 4.14
- 昨 收 4.28
- 总市值 885.46万
- 52周最高 91.2475
- 市盈率 静 --
- 换手率 1.81%
- 52周最低 3.13
- 委 比 -87.52%
- 总股本 206.40万
- 历史最高 21555.00
- 量 比 0.42
- 振 幅 6.06%
- 历史最低 3.25
- 每 手 1
- 风险率 9.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
Moleculin Biotech provided an update on its drug candidates Annamycin and WP1066. Annamycin is advancing in its pivotal Phase 2B/3 MIRACLE trial for second-line acute myeloid leukemia (AML), with expected milestones including data readouts, global expansion across nine countries, and the potential launch of a pancreatic cancer trial. WP1066, targeting brain tumors, is in a Phase 2 trial at Northwestern University and plans to begin a pediatric tr...
01-12 13:36
Moleculin Biotech Regains Nasdaq Listing Compliance; Delisting Hearing Canceled
As previously disclosed, on May 23, 2025, Moleculin Biotech, Inc. (the "Company") received a letter from the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), which
01-07 21:38
Moleculin Biotech Data From Phase Clinical Study Of WP1066 Demonstrates Anti-Tumor Immune Responses To Treat Pediatric Recurrent Malignant Brain Tumors
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced positive results from the Emory University physician-sponsored Phase 1 clinical trial conducted at the Aflac Cancer and Blood
2025-12-17 21:35
Moleculin Biotech Regains Nasdaq Compliance
The latest update is out from Moleculin Biotech ( ($MBRX) ). Moleculin Biotech,...
2025-12-17 06:55
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
Moleculin Biotech Enters Inducement Offer Agreements
Moleculin Biotech ( ($MBRX) ) has shared an announcement. On December 9, 2025, ...
2025-12-11 06:17
Moleculin announces exercise of warrants for $6.8M
Moleculin Biotech (MBRX) said on Wednesday that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain warrants to purchase up to an aggreg...
2025-12-10 22:07
Moleculin Biotech Raises $6.5M From Immediate Exercise Of 1,044,329 Warrants At $6.63 And $6.3219, Issues 2.61M New Warrants At $6.63
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has
2025-12-10 21:34
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds
Moleculin Biotech has entered into agreements to exercise certain outstanding warrants for up to 727,969 and 316,360 shares, raising $6.5 million. New warrants for 2,610,823 shares at $6.63 per share will be issued, exercisable upon shareholder approval. The company plans to use proceeds for working capital and general corporate purposes. The transaction is expected to close on December 11, 2025, subject to customary conditions. Moleculin is adva...
2025-12-10 13:30
Moleculin Biotech Partners With CIC biomaGUNE To Preclinically Test Annamycin For Glioblastoma Treatment
Investigator-Initiated Preclinical studies at CIC biomaGUNE aimed at combatting Glioblastoma Multiforme Research will evaluate effects of intra-arterial delivery of AnnamycinHOUSTON, Dec. 08, 2025 (GLOBE NEWSWIRE)
2025-12-08 21:21
